The observed correlation between p53 protein isoform expression and in vitro VPA sensitivity in primary AML cells indicates that patients with high levels of p53FL and low levels of p53β/γ would be more sensitive to treatment with VPA. The gene discussed is TP53; the disease is acute myeloid leukemia.